This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of Formula I, and pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof:



I

wherein

R^1 and R^2 are independently selected from the group consisting of OH, OC_{1-4}alkyl, and halo;

R^3 is C_{1-4}alkyl;

R^4 is selected from the group consisting of aryl and heteroaryl with both aryl and heteroaryl being unsubstituted or substituted with 1-5 groups independently selected from C_{1-4}alkyl, hydroxy-substituted C_{1-6}alkyl, OC_{1-4}alkyl, OH, CF_3, OCF_3, halo, SH, SC_{1-}

$_4$alkyl, NH_2, nitro, NHC_{1-4}alkyl, $N(C_{1-4}alkyl)(C_{1-4}alkyl)$, CN, C(O)OH, $C(O)OC_{1-4}$alkyl, $C(O)NHC_{1-4}$alkyl, $CH=N-OC_{1-4}$alkyl, $NHC(O)C_{1-4}$alkyl, $OC(O)C_{1-4}$alkyl, SOC_{1-4}alkyl, SO_2C_{1-4}alkyl, SO_2NHC_{1-4}alkyl and SO_2NH_2;

R^5 are either both H or together form $=CH_2$;

R^6 and R^7 are ~~independently~~ both H~~, C_{1-4}alkyl~~ or are taken together to form a C_{3-6}cycloalkyl ring;

x is 0-2; and

---- represents a single or a double bond.

2. (Original) The compound according to claim 1, wherein R^1 and R^2 are independently selected from the group consisting OH, OCH_3, and fluoro.

3. (Original) The compound according to claim 2, wherein R^1 and R^2 are both OH.

4. (Original) The compound according to claim 1, wherein R^3 is CH_3.

5. (Previously presented) The compound according to claim 1, wherein R^4 is selected from the group consisting of unsubstituted and substituted phenyl, pyridyl, thienyl, furanyl and pyrrolo.

6. (Original) The compound according to claim 5, wherein R^4 is selected from unsubstituted or substituted phenyl.

7. (Original) The compound according to claim 1, wherein both aryl and heteroaryl are either unsubstituted or substituted with 1-3 groups independently selected from C_{1-4}alkyl, hydroxy-substituted C_{1-6}alkyl, OC_{1-4}alkyl, OH, CF_3, OCF_3, halo, SH, SC_{1-4}alkyl, NH_2, NHC_{1-4}alkyl, $N(C_{1-4}alkyl)(C_{1-4}alkyl)$, CN, C(O)OH, $C(O)OC_{1-4}$alkyl, CH=N-OC_{1-4}alkyl, $C(O)NHC_{1-4}$alkyl, $NHC(O)C_{1-4}$alkyl, $OC(O)C_{1-4}$alkyl, SOC_{1-4}alkyl, SO_2C_{1-4}alkyl, SO_2NHC_{1-4}alkyl and SO_2NH_2.

8. (Original) The compound according to claim 7, wherein both aryl and heteroaryl are either unsubstituted or substituted with 1-2 groups independently selected from methyl, 3-hydroxy-3-pentyl, methoxy, OH, CF_3, OCF_3, halo, NH_2, NMe_2 and CH=N-OMe.

9. (Original) The compound according to claim 8, wherein both aryl and heteroaryl are either unsubstituted or substituted with 1-2 groups independently selected from methyl, 3-hydroxy-3-pentyl, Cl, F and CH=N-OMe.

10. (Previously presented) The compound according to claim 6, wherein R^4 is selected from the group consisting of phenyl,

4-chlorophenyl, 3,4-dichlorophenyl, 4-fluorophenyl, 4-methylphenyl, 3,4-difluorophenyl, 4-(3-hydroxy-3-pentyl)phenyl, 4-(CH=N-OMe)phenyl, 4-methoxyphenyl, 4-trifluoromethylphenyl and 4-nitrophenyl.

11. (Withdrawn) The compound according to claim 10, wherein R^4 is selected from the group consisting of 4-chlorophenyl, 3,4-dichlorophenyl, 4-(3-hydroxy-3-pentyl)phenyl, 4-fluorophenyl and 4-methylphenyl.

12. (Canceled).

13. (Currently amended) The compound according to claim ~~12~~ 1, wherein R^6 and R^7 are both H or are taken together to form a C_{3-4}cycloalkyl ring.

14. (Original) The compound according to claim 1, wherein x is 2.

15. (Original) The compound according to claim 1, wherein ---- represents a single bond.

16. (Currently amended) A compound of Formula I, and pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof:



I

wherein

R^1 and R^2 are independently selected from the group consisting of OH, OC_{1-4}alkyl, and halo;

R^3 is C_{1-4}alkyl;

R^4 is selected from the group consisting of aryl and heteroaryl with both aryl and heteroaryl being unsubstituted or substituted with 1-5 groups independently selected from C_{1-4}alkyl, hydroxy-substituted C_{1-6}alkyl, OC_{1-4}alkyl; OH, CF_3, OCF_3, halo, SH, SC_{1-4}alkyl, NH_2, nitro, NHC_{1-4}alkyl, $N(C_{1-4}alkyl)(C_{1-4}alkyl)$, CN, $C(O)OH$, $C(O)OC_{1-4}$alkyl, $C(O)NHC_{1-4}$alkyl, $NHC(O)C_{1-4}$alkyl, $OC(O)C_{1-4}$alkyl, SOC_{1-4}alkyl, SO_2C_{1-4}alkyl, SO_2NHC_{1-4}alkyl and SO_2NH_2;

R^5 are either both H or together form $=CH_2$;

R^6 and R^7 are ~~independently~~ both H~~, C_{1-4}alkyl~~ or are taken together to form a C_{3-6}cycloalkyl ring;

x is 0-2; and

---- represents a single or a double bond.

17. (Previously presented) A compound of Formula I, and pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof:



I

wherein

R^1 and R^2 are independently selected from the group consisting of OH, OC_{1-4}alkyl, and halo;

R^3 is C_{1-4}alkyl;

R^4 is selected from the group consisting of aryl and heteroaryl with both aryl and heteroaryl being unsubstituted or substituted with 1-5 groups independently selected from C_{1-4}alkyl, hydroxy-substituted C_{1-6}alkyl, OC_{1-4}alkyl, OH, CF_3, OCF_3, halo, SH, SC_{1-4}alkyl, NH_2, nitro, NHC_{1-4}alkyl, $N(C_{1-4}alkyl)(C_{1-4}alkyl)$, CN, C(O)OH, $C(O)OC_{1-4}$alkyl, $C(O)NHC_{1-4}$alkyl, CH=N-OC_{1-4}alkyl, $NHC(O)C_{1-4}$alkyl, $OC(O)C_{1-4}$alkyl, SOC_{1-4}alkyl, SO_2C_{1-4}alkyl, SO_2NHC_{1-4}alkyl and SO_2NH_2;

R^5 are either both H or together form $=CH_2$;

x is 0-2; and

---- represents a single or a double bond.

18. (Currently amended) The compound according to claim 1 selected from the group consisting of:



I(a) ;



I(c) ;



I(e) ;



I(g) ;



I(i) ;



I(k) ;



I(m) ;



I(o) ;



I(q) ;



I(s) ;



I(u) ;



I(v) ;



I(w) ;



I(x) ;



I(y) ;



I(aa) ;



I(cc) ;



I(ee) ;



I(gg) ;



I(ii) ;



I(jj) ;



I(ll) ;



I(nn) ;



I(oo) ;

and pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof.

19. (Previously presented) The compound according to claim 18, selected from the group consisting of I(a), I(e), I(g), I(i), I(m), I(o), I(q), I(u), I(cc), I(ee), I(jj), I(ll), I(nn) and I(oo).

20. (Previously presented) The compound according to claim 18, selected from the group consisting of I(a), I(e), I(g), I(i), I(u), I(cc), I(ee), I(jj), I(nn) and I(oo).

21-22. (Canceled).

23. (Original) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

24-67. (Canceled).